Tipifarnib

Generic Name
Tipifarnib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C27H22Cl2N4O
CAS Number
192185-72-1
Unique Ingredient Identifier
MAT637500A
Background

Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.

Indication

Investigated for use/treatment in colorectal cancer, leukemia (myeloid), pancreatic cancer, and solid tumors.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Tipifarnib in Subjects With Myelodysplastic Syndromes

Phase 2
Terminated
Conditions
Myelodysplastic Syndromes
Interventions
Drug: Tipifarnib
First Posted Date
2016-05-20
Last Posted Date
2024-07-31
Lead Sponsor
Kura Oncology, Inc.
Target Recruit Count
16
Registration Number
NCT02779777
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Columbia University Medical Center, New York, New York, United States

Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma

Phase 2
Conditions
Urothelial Carcinoma
Interventions
Drug: tipifarnib
First Posted Date
2015-08-28
Last Posted Date
2022-03-08
Lead Sponsor
Samsung Medical Center
Target Recruit Count
19
Registration Number
NCT02535650
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy

First Posted Date
2015-06-08
Last Posted Date
2024-06-26
Lead Sponsor
Kura Oncology, Inc.
Target Recruit Count
65
Registration Number
NCT02464228
Locations
🇪🇸

Hospital Universitari Vall d'Hebron, Barcelona, Spain

🇺🇸

Stanford University Medical Center, Palo Alto, California, United States

🇪🇸

Institut Catala d'Oncologia de Girona, Girona, Spain

and more 10 locations

Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations

First Posted Date
2015-03-10
Last Posted Date
2024-07-11
Lead Sponsor
Kura Oncology, Inc.
Target Recruit Count
63
Registration Number
NCT02383927
Locations
🇺🇸

Wihship Cancer Institute of Emory University, Atlanta, Georgia, United States

🇺🇸

Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, United States

🇺🇸

The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

and more 32 locations

Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

First Posted Date
2014-08-28
Last Posted Date
2014-12-23
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
19
Registration Number
NCT02227901
Locations
🇺🇸

Ronald Reagan UCLA Medical Center, Los Angeles, California, United States

Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders

First Posted Date
2014-08-07
Last Posted Date
2018-06-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
31
Registration Number
NCT02210858
Locations
🇺🇸

Stanford Cancer Institute, Palo Alto, California, United States

🇺🇸

University of Rochester, Rochester, New York, United States

Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia

First Posted Date
2011-05-26
Last Posted Date
2015-04-08
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
21
Registration Number
NCT01361464
Locations
🇺🇸

Emory University/Winship Cancer Institute, Atlanta, Georgia, United States

🇺🇸

Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States

🇺🇸

Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

and more 4 locations

Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia

First Posted Date
2008-01-28
Last Posted Date
2014-10-09
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
84
Registration Number
NCT00602771
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

🇺🇸

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

🇺🇸

Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States

and more 2 locations

Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer

First Posted Date
2007-05-07
Last Posted Date
2021-02-16
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
60
Registration Number
NCT00470301
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

🇺🇸

Columbia University Medical Center, New York, New York, United States

🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

and more 4 locations

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Phase 2
Completed
Conditions
Leukemia
Myelodysplastic Syndromes
First Posted Date
2007-03-30
Last Posted Date
2013-08-26
Lead Sponsor
The University of New South Wales
Target Recruit Count
2000
Registration Number
NCT00454480
Locations
🇬🇧

Queen's Hospital, Burton-upon-Trent, England, United Kingdom

🇬🇧

Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, England, United Kingdom

🇬🇧

Hereford Hospitals, Hereford, United Kingdom

and more 93 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy